Shimadzu Corporation launches ICPMS-2030, expanding solutions for elemental impurity analysis in pharmaceutical products
US pharmacopoeia indicates limits of elemental impurities (USP<232>) and detection technique by ICP-MS (USP<233>), which will be in effect in January 2018. In USP <735>, X-ray Fluorescence Spectrometry is adopted as general analytical method. For those demands, Shimadzu offers total solution for elemental impurities analysis from screening without sample preparation by the EDX-7000/8000, FDA 21 CFR Part 11 compliant Energy Dispersive X-ray Fluorescence Spectrometers, to high-sensitive and precision analysis by the ICPMS-2030.
The ICPMS-2030 will be exhibited at PITTCON 2016 from March 6th to 10th in Atlanta, GA, USA.
*ICH＝International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
1. Designed for High Sensitivity and Easy Maintenance
**Detection limits depend on elements.
2. Simplified Analysis and Higher Data Reliability by Assistant Functions and LabSolutions Software
Using the “Development Assistant" function, users can simply perform qualitative analysis by selecting the elements to be measured. The software then automatically sets the suitable analysis conditions. When performing routine analysis, “Diagnosis Assistant” automatically checks if there is spectral interference and indicates problems if there are any. Shimadzu FDA 21 CFR Part 11 compliant LabSolutions software provides ensured analytical data management.
3. Reduction of Argon Gas Consumption and Lower Running Cost by the Mini-torch and Eco Mode
ICPMS-2030 Inductively Coupled Plasma Mass Spectrometer
For Research Use Only. Not for use in diagnostic procedures.
This page may contain references to products that are not available in your country.
Please contact us to check the availability of these products in your country.